Aktis Oncology plans an upsized U.S. IPO, with Eli Lilly as a $100M anchor investorWhat happenedAktis Oncology is trying to price the first major U.S. IPO of 2026 with a bigger deal size than initially planned, and Eli Lilly stepping in as a major anchor investor. That combination is being read as a “biotech window might be reopening” signal.WinnersIPO GatekeepersA larger IPO means bigger underwriting fees, more biotech deal flow optimism, and more trading activity for IPO venues if the window stays open.Names: $JPM (JPMorgan Chase), $BAC (Bank of America), $TD (Toronto-Dominion Bank), $NDAQ (Nasdaq)Radiopharma / Nuclear MedicineIf investors reward a radiopharma IPO with demand, it can lift sentiment and flows into public radiopharma and theranostics names.Names: $LNTH (Lantheus Holdings), $CATX (Perspective Therapeutics), $RADX (Radiopharm Theranostics)Big Pharma Oncology DealmakersA blue-chip anchor ($LLY) can reinforce that big pharma still wants exposure to next-gen oncology platforms, supporting broader partnering/M&A optimism.Names: $LLY (Eli Lilly), $MRK (Merck)LosersCapital-Hungry Small-Cap BiotechA high-profile IPO can pull risk capital away from cash-burning small caps, raising dilution anxiety across the group.Names: $SANA (Sana Biotechnology), $FATE (Fate Therapeutics), $CRBU (Caribou Biosciences)Recent Biotech IPO CohortFresh IPOs can temporarily “steal the spotlight,” diverting volume and marginal bids from other recent new listings.Names: $MPLT (MapLight Therapeutics), $EVMN (Evommune), $LBRX (LB Pharmaceuticals)ADC / Nectin-4 Competitive CrowdAktis’ focus on Nectin-4 keeps the market’s attention on who has the best efficacy/safety and patient-selection story, which can pressure peers until they show standout data.Names: $PFE (Pfizer), $IPHA (Innate Pharma), $APVO (Aptevo Therapeutics)What to watch next$AKTS pricing vs. range ($16–$18) and day 1–3 trading: strong hold = risk-on for biotech; break issue = sentiment hit.Any follow-on headlines around radiopharma partnerships (especially involving $LLY).Read-through to radiopharma comps: $CATX, $RADX, $LNTH for sympathy moves/volume spikes.#StockMarket #Trading #Investing #DayTrading #SwingTrading #IPO #Biotech #Healthcare #Oncology #Pharma #Nasdaq #SmallCaps

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.